Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $293.7 million.

  • Cytokinetics' Non-Current Assets rose 10.00% to $459.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $459.2 million, marking a year-over-year increase of 10.00%. This contributed to the annual value of $293.7 million for FY2024, which is 49.66% up from last year.
  • Cytokinetics' Non-Current Assets amounted to $293.7 million in FY2024, which was up 49.66% from $196.3 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Non-Current Assets peaked at $305.6 million during FY2021, and registered a low of $59.6 million during FY2020.
  • For the 3-year period, Cytokinetics' Non-Current Assets averaged around $236.5 million, with its median value being $219.6 million (2022).
  • As far as peak fluctuations go, Cytokinetics' Non-Current Assets spiked by 412.99% in 2021, and later fell by 28.16% in 2022.
  • Yearly analysis of 5 years shows Cytokinetics' Non-Current Assets stood at $59.6 million in 2020, then skyrocketed by 412.99% to $305.6 million in 2021, then decreased by 28.16% to $219.6 million in 2022, then decreased by 10.62% to $196.3 million in 2023, then surged by 49.66% to $293.7 million in 2024.